Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 637


Characterising acquired resistance to erlotinib in non-small cell lung cancer patients.

Karachaliou N, Codony-Servat J, Bracht JWP, Ito M, Filipska M, Pedraz C, Chaib I, Bertran-Alamillo J, Cardona AF, Molina MA, Rosell R.

Expert Rev Respir Med. 2019 Aug 19:1-10. doi: 10.1080/17476348.2019.1656068. [Epub ahead of print]


PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around.

Gkountakos A, Sartori G, Falcone I, Piro G, Ciuffreda L, Carbone C, Tortora G, Scarpa A, Bria E, Milella M, Rosell R, Corbo V, Pilotto S.

Cancers (Basel). 2019 Aug 9;11(8). pii: E1141. doi: 10.3390/cancers11081141. Review.


Dacomitinib for the first-line treatment of patients with EGFR-mutated metastatic non-small cell lung cancer.

Santarpia M, Menis J, Chaib I, Gonzalez Cao M, Rosell R.

Expert Rev Clin Pharmacol. 2019 Aug 5:1-10. doi: 10.1080/17512433.2019.1649136. [Epub ahead of print]


Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives.

Karachaliou N, Fernandez Bruno M, Bracht JWP, Rosell R.

Onco Targets Ther. 2019 Jun 13;12:4567-4575. doi: 10.2147/OTT.S174548. eCollection 2019. Review.


Effects of dose modifications on the safety and efficacy of dacomitinib for EGFR mutation-positive non-small-cell lung cancer.

Corral J, Mok TS, Nakagawa K, Rosell R, Lee KH, Migliorino MR, Pluzanski A, Linke R, Devgan G, Tan W, Quinn S, Wang T, Wu YL.

Future Oncol. 2019 Aug;15(24):2795-2805. doi: 10.2217/fon-2019-0299. Epub 2019 Jul 17.


Investigation of chronic and persistent classical swine fever infections under field conditions and their impact on vaccine efficacy.

Coronado L, Bohórquez JA, Muñoz-González S, Perez LJ, Rosell R, Fonseca O, Delgado L, Perera CL, Frías MT, Ganges L.

BMC Vet Res. 2019 Jul 15;15(1):247. doi: 10.1186/s12917-019-1982-x.


Assessing lake ecological status across a trophic gradient through environmental and biological variables.

Macintosh KA, Cromie H, Forasacco E, Gallagher K, Kelly FL, McElarney Y, O'Kane E, Paul A, Rippey B, Rosell R, Vaughan L, Ward C, Griffiths D.

Sci Total Environ. 2019 Jul 4;690:831-840. doi: 10.1016/j.scitotenv.2019.07.038. [Epub ahead of print]


Salvage surgery after definitive chemo-radiotherapy for patients with Non-Small Cell Lung Cancer.

Romero-Vielva L, Viteri S, Moya-Horno I, Toscas JI, Maestre-Alcácer JA, Ramón Y Cajal S, Rosell R.

Lung Cancer. 2019 Jul;133:117-122. doi: 10.1016/j.lungcan.2019.05.010. Epub 2019 May 13.


Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.

Mazières J, Drilon A, Lusque A, Mhanna L, Cortot AB, Mezquita L, Thai AA, Mascaux C, Couraud S, Veillon R, Van Den Heuvel M, Neal J, Peled N, Früh M, Ng TL, Gounant V, Popat S, Diebold J, Sabari J, Zhu VW, Rothschild SI, Bironzo P, Martinez A, Curioni-Fontecedro A, Rosell R, Lattuca-Truc M, Wiesweg M, Besse B, Solomon B, Barlesi F, Schouten RD, Wakelee H, Camidge DR, Zalcman G, Novello S, Ou SI, Milia J, Gautschi O.

Ann Oncol. 2019 May 24. pii: mdz167. doi: 10.1093/annonc/mdz167. [Epub ahead of print]


Correction: Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer.

Morán T, Felip E, Bosch-Barrera J, de Aguirre I, Ramirez JL, Mesia C, Carcereny E, Roa D, Sais E, García Y, Blanco R, Sanchez S, Villacorta CR, Queralt C, Velarde JM, Rosell R.

Oncotarget. 2019 Apr 2;10(26):2576. doi: 10.18632/oncotarget.26855. eCollection 2019 Apr 2.


Multigene Mutation Profiling and Clinical Characteristics of Small-Cell Lung Cancer in Never-Smokers vs. Heavy Smokers (Geno1.3-CLICaP).

Cardona AF, Rojas L, Zatarain-Barrón ZL, Ruiz-Patiño A, Ricaurte L, Corrales L, Martín C, Freitas H, Cordeiro de Lima VC, Rodriguez J, Avila J, Bravo M, Archila P, Carranza H, Vargas C, Otero J, Barrón F, Karachaliou N, Rosell R, Arrieta O.

Front Oncol. 2019 Apr 17;9:254. doi: 10.3389/fonc.2019.00254. eCollection 2019.


Consistency and reproducibility of next-generation sequencing in cytopathology: A second worldwide ring trial study on improved cytological molecular reference specimens.

Pisapia P, Malapelle U, Roma G, Saddar S, Zheng Q, Pepe F, Bruzzese D, Vigliar E, Bellevicine C, Luthra R, Nikiforov YE, Mayo-de-Las-Casas C, Molina-Vila MA, Rosell R, Bihl M, Savic S, Bubendorf L, de Biase D, Tallini G, Hwang DH, Sholl LM, Vander Borght S, Weynand B, Stieber D, Vielh P, Rappa A, Barberis M, Fassan M, Rugge M, De Andrea CE, Lozano MD, Lupi C, Fontanini G, Schmitt F, Dumur CI, Bisig B, Bongiovanni M, Merkelbach-Bruse S, Büttner R, Nikiforova MN, Roy-Chowdhuri S, Troncone G; Molecular Cytopathology Meeting Group.

Cancer Cytopathol. 2019 May;127(5):285-296. doi: 10.1002/cncy.22134. Epub 2019 Apr 25.


AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy.

Bertran-Alamillo J, Cattan V, Schoumacher M, Codony-Servat J, Giménez-Capitán A, Cantero F, Burbridge M, Rodríguez S, Teixidó C, Roman R, Castellví J, García-Román S, Codony-Servat C, Viteri S, Cardona AF, Karachaliou N, Rosell R, Molina-Vila MA.

Nat Commun. 2019 Apr 18;10(1):1812. doi: 10.1038/s41467-019-09734-5.


Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial.

Michels S, Massutí B, Schildhaus HU, Franklin J, Sebastian M, Felip E, Grohé C, Rodriguez-Abreu D, Abdulla DSY, Bischoff H, Brandts C, Carcereny E, Corral J, Dingemans AC, Pereira E, Fassunke J, Fischer RN, Gardizi M, Heukamp L, Insa A, Kron A, Menon R, Persigehl T, Reck M, Riedel R, Rothschild SI, Scheel AH, Scheffler M, Schmalz P, Smit EF, Limburg M, Provencio M, Karachaliou N, Merkelbach-Bruse S, Hellmich M, Nogova L, Büttner R, Rosell R, Wolf J.

J Thorac Oncol. 2019 Jul;14(7):1266-1276. doi: 10.1016/j.jtho.2019.03.020. Epub 2019 Apr 9.


Experimental infection with high- and low-virulence strains of border disease virus (BDV) in Pyrenean chamois (Rupicapra p. pyrenaica) sheds light on the epidemiological diversity of the disease.

Colom-Cadena A, Marco I, Fernández Aguilar X, Velarde R, Espunyes J, Rosell R, Lavín S, Cabezón O.

Transbound Emerg Dis. 2019 Jul;66(4):1619-1630. doi: 10.1111/tbed.13195. Epub 2019 Apr 29.


Disulfide isomerase family-6 mediates cisplatin resistance by interfering with apoptosis and autophagy.

Rosell R, Karachaliou N.

EBioMedicine. 2019 Apr;42:20-21. doi: 10.1016/j.ebiom.2019.03.088. Epub 2019 Apr 5. No abstract available.


Co-mutations in EGFR driven non-small cell lung cancer.

Rosell R, Karachaliou N.

EBioMedicine. 2019 Apr;42:18-19. doi: 10.1016/j.ebiom.2019.03.037. Epub 2019 Mar 20. No abstract available.


Cancer Stem Cell Biomarkers in EGFR-Mutation-Positive Non-Small-Cell Lung Cancer.

Codony-Servat J, Codony-Servat C, Cardona AF, Giménez-Capitán A, Drozdowskyj A, Berenguer J, Bracht JWP, Ito M, Karachaliou N, Rosell R.

Clin Lung Cancer. 2019 May;20(3):167-177. doi: 10.1016/j.cllc.2019.02.005. Epub 2019 Feb 21.


Association between the novel classification of lung adenocarcinoma subtypes and EGFR/KRAS mutation status: A systematic literature review and pooled-data analysis.

Jiang L, Mino-Kenudson M, Roden AC, Rosell R, Molina MÁ, Flores RM, Pilz LR, Brunelli A, Venuta F, He J; AME Lung Cancer Collaborative Group.

Eur J Surg Oncol. 2019 May;45(5):870-876. doi: 10.1016/j.ejso.2019.02.006. Epub 2019 Feb 16.


A Single-Center Retrospective Study of Patients with Double Primary Cancers: Breast Cancer and EGFR-Mutant Non-Small Cell Lung Cancer.

Moran T, Quiroga V, Cirauqui B, Vila L, Gil-Moreno M, Carcereny E, Margeli M, Muñoz-Marmol A, Mate JL, Velarde JM, Molina MA, Rosell R.

Oncol Res Treat. 2019;42(3):107-114. doi: 10.1159/000495666. Epub 2019 Feb 23.


Supplemental Content

Loading ...
Support Center